Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Julio Vijil

Nephrology Hollywood, FL Medical Doctor

NPI 1114030673 CMS profile 141431

1150 N 35Th Ave, Suite 465, Hollywood, FL 33021

Open in the dashboard

General payments

$29,021

59 records reported · program years 2019–2024

Research payments

$39,252

Paid to them · 17 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$16,074,681 paid to institutions, not to them · program years 2021–2025

Through program year 2024, Julio Vijil of Hollywood, FL is reported in the CMS Open Payments database as having received $29,021 across 59 general payments and $39,252 in research payments paid to them. Separately, studies naming them as principal investigator received $16,074,681 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $18,656 2
2024 Research $39,252 17
2023 General $4,610 26
2022 General $1,288 13
2021 General $3,291 5
2020 General $951 3
2019 General $226 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julio Vijil
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Julio Vijil were reported at $0. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Julio Vijil Nephrology median Middle half National median
2019 $226 $236 $90–$588 $163
2020 $951 $135 $46–$364 $114
2021 $3,291 $202 $67–$551 $132
2022 $1,288 $242 $77–$695 $149
2023 $4,610 $254 $84–$766 $160
2024 $18,656 $300 $99–$852 $164
2025 $0 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Pfizer Inc. $18,585 1 payment
  2. Merck Sharp & Dohme Corporation $5,230 38 payments
  3. AstraZeneca Pharmaceuticals LP $4,077 7 payments
  4. Moderna TX, Inc. $668 1 payment
  5. Amgen Inc. $172 7 payments
  6. Alexion Pharmaceuticals, Inc. $150 1 payment
  7. Corcept Therapeutics $71 1 payment
  8. Mallinckrodt Enterprises LLC $26 1 payment
  9. Akebia Therapeutics Inc $24 1 payment
  10. Otsuka America Pharmaceutical, Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $18,585 1 payment
  2. Travel and Lodging $4,312 21 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,900 3 payments
  4. Food and Beverage $2,075 33 payments
  5. Honoraria $150 1 payment
Products named General payments · program years 2019–2024
  1. LOKELMA $4,077 7 payments
  2. Soliris $150 1 payment
  3. Parsabiv Nephrology $145 6 payments
  4. CAPVAXIVE $35 1 payment
  5. Parsabiv Nephrology $27 1 payment
  6. ACTHAR $26 1 payment
  7. Auryxia $24 1 payment
  8. JYNARQUE $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Eli Lilly and Company $35,466 1 payment
  2. Corcept Therapeutics $3,786 16 payments

Records

76 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record